Status:

WITHDRAWN

TIXAGEVIMAB/CILGAVIMAB Protection of Covid-19 in Transplanted Patients

Lead Sponsor:

Hospices Civils de Lyon

Conditions:

Solid Organ Transplant Recipients

Eligibility:

All Genders

18+ years

Brief Summary

Covid-19 has a very bad prognosis in solid organ transplant recipients with a 60 days-mortality exceeding 20%. For this reason, transplant patients were prioritized to receive Covid-19 vaccination sin...

Eligibility Criteria

Inclusion

  • Male or female, 18 years of age or older
  • Recipient of a solid organ transplant
  • Subject affiliated with a health insurance company
  • Patient able to understand the objectives and risks of the research and to give a non-objection
  • Patient with a post-vaccination anti-Spike IgG (or RBD - Receptor Blinding Domain) titer of less than 30 BAU/ml ( (binding antibody units) measured at least 14 days after completion of an intensified vaccination regimen (at least 3 doses of mRNA vaccine) and prior to administration of anti-SARS-Cov-2 monoclonal antibodies.
  • Group 1 criteria: Naïve patients, never having received anti-SARS CoV2 monoclonal antibodies.
  • Group 2 criteria: Patients who have previously received anti-SARS Cov2 monoclonal antibodies

Exclusion

  • History of anaphylactic shock or known allergy to TIXAGEVIMAB/CILGAVIMAB
  • Known history of Covid-19 or positive Covid-19 serology within 3 months prior to inclusion
  • History of myocardial infarction or coronary artery disease within 3 months prior to inclusion
  • Contraindication to an intramuscular injection
  • Impossibility to give to the subject an informed information
  • Subject under legal protection, guardianship or curatorship
  • Plasmapheresis in progress or planned
  • Weight less than 48 kg
  • Patient participating in another interventional research study in progress
  • Pregnant, parturient, or breastfeeding women

Key Trial Info

Start Date :

February 1 2022

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 1 2023

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT05234398

Start Date

February 1 2022

End Date

August 1 2023

Last Update

September 1 2022

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Service de Néphrologie, Transplantation et Immunologie Clinique Hôpital Edouard Herriot - Hospices Civils de Lyon

Lyon, France, 69437

2

Service de Néphrologie et Transplantation, Hôpitaux Universitaires de Strasbourg

Strasbourg, France, 67091